Short Courses*

MONDAY, AUGUST 19
MORNING, 9:00 am–12:00 pm

SC1: Technologies, Applications and Commercialization of POC Dx - Detailed Agenda

Holger Becker, PhD, Founder & CSO, microfluidic ChipShop GmbH

This short course will provide an overview on the technological aspects of POC system developments. It will introduce current technologies such as microfluidics, sensors, paper- and smartphone-based approaches and discuss their trends and limitations. The course will discuss a variety of POC systems in different stages of their development, from early stage to established diagnostic systems in the clinical routine. Market aspects of POC systems as well as practical examples of commercialization for molecular diagnostic, immunological and clinical tests will be presented.

SC2: Discover How Machine Learning Can Complement Diagnoses through Medical Imagery - Detailed Agenda

Helen Lam, Software Developer, Developer Advocate, IBM Watson

Nicholas Bourdakos, Software Developer, IBM Watson

In this hands-on session, learn how to train your own custom classifier using medical images to help augment your diagnoses. We will first cover the overview of available technologies for medical imagery in diagnosis, then will show examples by utilizing Watson Machine Learning and Tensorflow, an open source software library for high performance numerical computation to create a custom model.

SC3: Emerging Applications of ctDNA

John Simmons, PhD, Vice President, Translational Medicine, Personal Genome Diagnostics

This short course will cover cutting edge applications and clinical trials that use ctDNA for monitoring, minimal residual disease, and plasma tumor mutation burden. The background basics, the technologies, the clinical evidence out there so far, and the highlights of the prospective designs that are underway will be discussed.

AFTERNOON, 2:00–5:00 pm

SC7: Digital Pathology from A to Z for Beginners - Detailed Agenda

Matthew G. Hanna, MD, Clinical Instructor, Breast and Informatics, Department of Pathology, Memorial Sloan Kettering Cancer Center

Digital pathology is a disruptive technology in the laboratory workflow. It has tremendous potential to change the way pathologists, researchers, and other personnel interact with pathology data. It is an exciting era of potentially practice-changing technology. Although digital pathology comes with significant promise, there are still numerous obstacles that stand in the way of becoming the next standard of care. Aside from clinical practice, digital pathology can be leveraged in the research and education arms of the medical community. This course will cover the nuts and bolts for all related topics in digital pathology for those who are just wondering what all the hype is about, to those who want a little more depth in their understanding of what digital pathology can and will do in the medical community.

SC8: Tumor Mutation Burden: Unloading the Latest Challenges and Developments - Detailed Agenda

Susan J. Hsiao, MD, PhD, Assistant Professor, Pathology and Cell Biology, Columbia University Medical Center

Larissa V. Furtado, MD, Medical Director, Molecular Oncology, ARUP Laboratories; Associate Professor of Pathology, University of Utah School of Medicine

Ahmet Zehir, PhD, Director, Clinical Bioinformatics, Memorial Sloan Kettering Cancer Center

In this short course, we will review the current state of the field for tumor mutational burden (TMB), a biomarker predictive of response to immunotherapy agents. This course will cover concepts including the clinical utility of measuring TMB, technical considerations and challenges in validating and measuring TMB in a clinical laboratory, issues surrounding clinical TMB interpretation, and future directions and applications of TMB testing.

SC9: Liquid Biopsies based on Extracellular Vesicles: Prospects, Challenges, and Opportunities

Joshua T. Smith, PhD, Research Staff Member, Translational Systems Biology and Nanobiotechnology, IBM T. J. Watson Research Center

Additional Speaker to be Announced

Extracellular vesicles (EVs) exhibit a number of properties that make them attractive as a rich source of biomarkers for disease diagnosis, treatment monitoring, and therapeutics, including their abundance in a wide breadth of bodily fluids, nucleic acid and protein content, and protective lipid membrane that preserves this cargo from degradation. This course reviews key discoveries in EV research, describes current efforts to exploit their properties to capture market value, and takes a look at exploratory and emerging technologies aimed at accelerating their study and use. Existing gaps in understanding along with current efforts to address these unknowns will also be elucidated.

WednesDAY, AUGUST 21
DINNER, 6:45–9:15 pm

SC13: Data-Driven Process Development in the Clinical Laboratory

Robert Young, CGMBS, MS Bioinformatics, Owner, Principal Consultant, Lab Insights, LLC

The modern clinical laboratory utilizes complex, data-rich computer systems. In this course, you will learn how to leverage your laboratory information systems to build data-driven processes, create data-driven process improvements, and make data-driven business decisions.

SC14: Generating Evidence and Creating a Winning Dossier for Regulatory and Reimbursement Needs

Mark Hiatt, MD, Vice President, Guardant Health

John Sninsky, PhD, Consultant, Translational Sciences

Managing the clinical narrative for your diagnostic test requires careful evaluation of the evidentiary requirements of stakeholders. Using those evidentiary requirements to determine your clinical and economic study designs is the cornerstone of effective product development.

SC15: Microfluidics and Lab-on-a-Chip Devices for POCT: Technologies and Commercialization - Detailed Agenda

Chris Myatt, Founder & CEO, MBio Diagnostics, Inc.

Additional Speakers to be Announced

This short course will provide an overview of microfluidic techniques, including valved and valve-less devices, pumped systems, and capillary flow approaches. Practical examples will keep the discussion grounded in the realization of commercializable devices. We will discuss engineering approaches to enhance the advantages and minimize the challenges. Throughout, the science will be linked to the commercial case for these devices, including a full discussion of a recent success story of a centrifugal microfluidic molecular assay system.

SC16: Development of Novel Diagnostics for Antimicrobial Resistance

Diane L. Dutt, PhD, PMP, Science and Technology Manager, Diagnostics and Detection Division, Defense Threat Reduction Agency

Nathan W. Adams MBA, PhD, Program Manager, Contracting Officer’s Representative Defense Threat Reduction Agency, RD-CBA Joint CBRN Center of Excellence Defense Threat Reduction Agency

Stephen C. Francesconi, PhD, Diagnostics and Detection Division, Defense Threat Reduction Agency